EUVIMEDEUVIMED entdecken
Crossref

FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma

Sakura Hiraide Taniguchi, Keigo Komine, Noriko Takenaga, Yuya Yoshida, Keiju Sasaki, Yoshifumi Kawamura, Yuki Kasahara, Kota Ouchi, Hiroo Imai, Ken Saijo, Hidekazu Shirota, Masanobu Takahashi und 1 weitere

Anticancer Research · 2023

DOI: 10.21873/anticanres.16775 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Sakura Hiraide Taniguchi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Camptothecin. Die Arbeit wurde bisher 4-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Urachal carcinoma is a rare cancer, with limited evidence regarding systemic chemotherapy for metastatic urachal carcinoma. This study aimed to evaluate the efficacy and safety of a combination therapy of 5-fluorouracil and irinotecan (FOLFIRI) in patients with metastatic urachal carcinoma. PATIENTS AND METHODS: Patients with metastatic urachal carcinoma treated with FOLFIRI between March 2008 and April 2023 at the Department of Medical Oncology, Tohoku University Hospital, were retrospectively analyzed using medical records. RESULTS: Six patients with urachal carcinoma received FOLFIRI. The histological type was adenocarcinoma in all patients. The metastatic or recurrent sites were the peritoneum, lungs, lymph nodes, and local relapse sites. Three patients received FOLFIRI as first-line chemotherapy, and the other three received FOLFIRI as second-line chemotherapy. Two patients had only non-measurable lesions as the targets of tumor response. The best response was the stable disease or non-complete response/non-progressive disease in four patients, with a disease control rate of 67%. The median progression-free survival was 7.5 months. In two patients with ascites only as the site of metastasis, the amount of ascites and serum tumor marker levels decreased after FOLFIRI was initiated. Grade 3/4 toxicities included grade 3 neutropenia in one patient and grade 3 diarrhea in one patient. CONCLUSION: FOLFIRI has modest efficacy and good tolerability for the treatment of metastatic urachal carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsCamptothecinRetrospective StudiesLeucovorinAntineoplastic Combined Chemotherapy ProtocolsHumansTreatment OutcomeFluorouracilAscitesNeoplasm Recurrence, LocalUrinary Bladder Neoplasms

Stichwörter der Autor:innen

5-fluorouracil and irinotecan (FOLFIRI)Urachal carcinomasystemic chemotherapy

Substanzen

CamptothecinLeucovorinFluorouracil

Autor:innen und Institutionen

  • Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
  • Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.
  • Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan; chikashi@tohoku.ac.jp.

Zitieren

APA

Taniguchi, S. H., Komine, K., Takenaga, N., Yoshida, Y., Sasaki, K., Kawamura, Y., Kasahara, Y., Ouchi, K., Imai, H., Saijo, K., Shirota, H., Takahashi, M., & Ishioka, C. (2023). FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.16775

Vancouver

Taniguchi SH, Komine K, Takenaga N, Yoshida Y, Sasaki K, Kawamura Y, et al. FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma. Anticancer Research. 2023. doi:10.21873/anticanres.16775

BibTeX
@article{Taniguchi2023,
  author = {Taniguchi, Sakura Hiraide and Komine, Keigo and Takenaga, Noriko and Yoshida, Yuya and Sasaki, Keiju and Kawamura, Yoshifumi and Kasahara, Yuki and Ouchi, Kota and Imai, Hiroo and Saijo, Ken and Shirota, Hidekazu and Takahashi, Masanobu and Ishioka, Chikashi},
  title = {FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma},
  journal = {Anticancer Research},
  year = {2023},
  doi = {10.21873/anticanres.16775}
}
Kostenlos starten →